Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.48 |
| ▸ | FAAH | O00519 | 7/20 | 0.43 |
| ▸ | CES1 | P23141 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15201844 | 1.00 | CES2 (0.50) | CES2LPAR1LPAR3GGPS1FAAH | |
| SCHEMBL4647180 | 0.78 | GGPS1 (0.52) | CES2LPAR1LPAR3GGPS1TSHR | |
| SCHEMBL21004295 | 0.78 | CES2 (0.48) | CES2LPAR1LPAR3GGPS1FAAH | |
| SCHEMBL18214509 | 0.78 | TSHR (0.47) | CES2LPAR1LPAR3GGPS1TSHR | |
| SCHEMBL24761193 | 0.78 | LPAR1 (0.54) | CES2LPAR1LPAR3GGPS1FAAH | |
| SCHEMBL24926244 | 0.78 | CES2 (0.48) | CES2LPAR1LPAR3GGPS1FAAH | |
| SCHEMBL23034428 | 0.78 | LPAR1 (0.54) | CES2LPAR1LPAR3GGPS1FAAH | |
| SCHEMBL24761094 | 0.78 | LPAR1 (0.54) | CES2LPAR1LPAR3GGPS1FAAH | |
| SCHEMBL21004248 | 0.78 | CES2 (0.48) | CES2LPAR1LPAR3GGPS1FAAH | |
| SCHEMBL23716824 | 0.78 | GGPS1 (0.52) | CES2LPAR1LPAR3GGPS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916513-B2 | Dioxirane compounds and uses thereof | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140187467-A1 | DIOXIRANE COMPOUNDS AND USES THEREOF | CRESTLINE DIRECT FINANCE, L.P. | 2014-07-03 | — | — | US | disclosed |
| WO-2013122582-A1 | DIOXIRANE COMPOUNDS AND USES THEREOF | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2013-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187467-A1 | DIOXIRANE COMPOUNDS AND USES THEREOF | DUOX2, DECR2, SCO2 | CES2 682/4885LPAR1 357/4885LPAR3 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.